Oxytocin Effects on Food Motivation Pathways

Overweight and Obesity Clinical Trial

Official title:

Oxytocin Effects on Food Motivation Pathways

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02276677
• Other study ID #: SPID 1127
• Status: Completed
• Phase: Early Phase 1
• Start date: October 2014
• Est. completion date: May 2015

Study information

• Verified date: April 2019
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Oxytocin is a peptide hormone produced in the brain that regulates food intake. However, the mechanisms for this effect in humans is not yet clear.

In this study, the investigators will therefore examine the effect of a single dose of intranasal oxytocin (compared to placebo) on levels of appetite-regulating hormones and functional magnetic resonance imaging activation of areas of the brain involved in food motivation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: May 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Age 18-45 years old

• BMI 25-40

• Regular breakfast eater (at least 4 times per week)

• Stable weight within the past three months

Exclusion Criteria:

• Psychiatric disease, use of psychotropic medications

• History of eating disorder

• History of excessive exercise within the last three months (having run more that 25 miles in any one week or having exercised more than ten hours in any one week)

• History of diabetes mellitus

• Active substance abuse

• Hematocrit lower than the normal range

• Gastrointestinal tract surgery (including gastrectomy, gastric bypass surgery, and small or large bowel resection)

• History of cardiovascular disease (such as hypertrophic cardiomyopathy, valvular heart disease, coronary heart disease, or coronary artery spasms)

• Untreated thyroid disease

• Tobacco use

• Cardiac pacemaker, surgical aneurysm clips, neurostimulator, implanted pumps, metal fragments in body/eyes, nitroglycerin patch, severe claustrophobia

Related Conditions & MeSH terms

• Overweight
• Overweight and Obesity

Intervention

Drug:
• Oxytocin
Single dose, intranasal
• Placebo
Single dose, intranasal

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in functional magnetic resonance imaging activation of food motivation brain regions		Functional magnetic resonance imaging at T60 min after oxytocin/placebo
Secondary	Change in hormone levels (cholecystokinin, glucagon-like peptide-1)		Blood draws at T0, T30, T60, T120 min after oxytocin/placebo